PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION

• Juan Du,
• Haiyan He,
• Xiangqiang Fan,
• Lina Jin,
• Jing Lu,
• Wanting Qiang,
• Jin Liu

Affiliations

Juan Du

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China

Haiyan He

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China

Xiangqiang Fan

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China

Lina Jin

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China

Jing Lu

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China

Wanting Qiang

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China

Jin Liu

1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China